Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 1Pancreatic Neoplasms 1Neoplasms 1Liver Diseases 1Adenocarcinoma 1

Interventions

Dexamethasone 4pomalidomide 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gallium 68 PSMA-11 1copanlisib 1carfilzomib 1belinostat 1belantamab mafodotin 1Zoledronic Acid 1Topotecan 1Tablets 1Sitagliptin Phosphate 1Pluvicto 1Paclitaxel 1Lenalidomide 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Renal Insufficiency × rubitecan × Clear all
NCT00113113 2024-08-02

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Astex Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled

Liver Diseases, Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡